X
[{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for PB2452
Filters
Companies By Therapeutic Area
Details:
The collaboration with SFJ provides PhaseBio with substantial funding to continue the rapid advancement of lead program, PB2452.
Lead Product(s):
PB2452
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
SFJ Pharmaceuticals
Deal Size: $120.0 million
Upfront Cash: Undisclosed
Deal Type: Collaboration
January 10, 2020